The renin angiotensin system and the metabolic syndrome

Physiology and Behavior

Volumn 100, Issue 5, 2010, Pages 525-534

  de Kloet, Annette D ^a   Krause, Eric G ^b   Woods, Stephen C ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Adipose; Angiotensin; Diabetes; Food intake; Obesity; Renin

Indexed keywords

ANGIOTENSIN II;

ADIPOCYTE; ADIPOGENESIS; ANGIOGENESIS; ARTICLE; BODY WEIGHT; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN TISSUE; BROWN ADIPOSE TISSUE; CELL GROWTH; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; ELECTROENCEPHALOGRAM; ENERGY BALANCE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKELETAL MUSCLE; WHITE ADIPOSE TISSUE;

ANIMALS; BODY WEIGHT; HUMANS; INSULIN; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM;

EID: 77953713390     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.03.018     Document Type: Article

References (156)

1. James W.P.T. The epidemiology of obesity: the size of the problem. J Intern Med 2008, 263(4):336-352.
2. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295(13):1549-1555.
3. de Kloet A.D., Krause E.G., Kim D.H., Sakai R.R., Seeley R.J., Woods S.C. The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 2009, 150(9):4114-4123.
4. Jayasooriya A.P., Mathai M.L., Walker L.L., Begg D.P., Denton D.A., Cameron-Smith D., et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci 2008, 105(18):6531-6536.
5. Massiera F., Seydoux J., Geloen A., Quignard-Boulange A., Turban S., Saint-Marc P., et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001, 142(12):5220-5225.
6. Weisinger H.S., Begg D.P., Egan G.F., Jayasooriya A.P., Lie F., Mathai M.L., et al. Angiotensin converting enzyme inhibition from birth reduces body weight and body fat in Sprague-Dawley rats. Physiol Behav 2008, 93(4-5):820.
7. Abuissa H., Jones P.G., Marso S.P., O'Keefe J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46(5):821-826.
8. Niklason A., Hedner T., Niskanen L., Lanke J. Development of diabetes is retarded by ACE inhibition in hypertensive patients-a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004, 22(3):645-652.
9. Gillespie E.L., White C.M., Kardas M., Lindberg M., Coleman C.I. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005, 28(9):2261-2266.
10. Parhofer K.G., Munzel F., Krekler M. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 2007, 6:36.
11. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004, 30(6):498-505.
12. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004, 30(6):487-496.
13. Mori Y., Itoh Y., Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007, 20(4):431-436.
14. Santos E.L., de Picoli Souza K., Guimarães P.B., Reis F.C.G., Silva S.M.A., Costa-Neto C.M., et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 2008, 8(2):247.
15. Shiuchi T., Iwai M., Li H.-S., Wu L., Min L.-J., Li J.-M., et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004, 43(5):1003-1010.
16. Takahashi N., Li F., Hua K., Deng J., Wang C.-H., Bowers R.R., et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007, 6(6):506.
17. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005, 146(8):3481-3489.
18. Yvan-Charvet L., Even P., Bloch-Faure M., Guerre-Millo M., Moustaid-Moussa N., Ferre P., et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005, 54(4):991-999.
19. Krause E.G., Sakai R.R. Richter and sodium appetite: from adrenalectomy to molecular biology. Appetite 2007, 49(2):353-367.
20. Santos R.A., Ferreira A.J., Simoes E.S.A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008, 93(5):519-527.
21. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003, 100(14):8258-8263.
22. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275(43):33238-33243.
23. Wright J.W., Stubley L., Pederson E.S., Kramar E.A., Hanesworth J.M., Harding J.W. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999, 19(10):3952-3961.
24. Yayama K., Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008, 8(2):312.
25. Sadoshima J., Qiu Z.H., Morgan J.P., Izumo S. Angiotensin-Ii and other hypertrophic stimuli mediated by G-protein-coupled receptors activate tyrosine kinase, mitogen-activated protein-kinase, and 90-Kd S6 kinase in cardiac myocytes-the critical role of Ca2+-dependent signaling. Circ Res 1995, 76(1):1-15.
26. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J.A., Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci 1996, 93(22):12490-12495.
27. Daniels D., Mietlicki E.G., Nowak E.L., Fluharty S.J. Angiotensin II stimulates water and NaCl intake through separate cell signalling pathways in rats. Exp Physiol 2009, 94(1):130-137.
28. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86(3):747-803.
29. Li Z., Ferguson A.V. Subfornical organ efferents to paraventricular nucleus utilize angiotensin as a neurotransmitter. Am J Physiol Regul Integr Comp Physiol 1993, 265(2):R302-R309.
30. Massiéra F., Bloch-Faure M., Ceiler D., Murakami K., Fukamizu A., Gasc J.-M., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 01-0457fje.
31. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109(11):1417-1427.
32. Cuadra A.E., Shan Z., Sumners C., Raizada M.K. Acurrent viewof brain renin-angiotensin system: is the (pro)renin receptor the missing link?. Pharmacol Ther 2010, 125(1):27-38.
33. Nguyen G., Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr Opin Pharmacol 2008, 8(2):127-132.
34. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87(5):E1-E9.
35. Gembardt F., Sterner-Kock A., Imboden H., Spalteholz M., Reibitz F., Schultheiss H.P., et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 2005, 26(7):1270-1277.
36. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005, 280(34):30113-30119.
37. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F., Heringer-Walther S., Sexton P.M., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005, 111(14):1806-1813.
38. Boustany C.M., Bharadwaj K., Daugherty A., Brown D.R., Randall D.C., Cassis L.A. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004, 287(4):R943-R949.
39. Schmieder R.E., Hilgers K.F., Schlaich M.P., Schmidt B.M.W. Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369(9568):1208.
40. Alderman M.H., Madhavan S., Ooi W.L., Cohen H., Sealey J.E., Laragh J.H. Association of the renin sodium profile with the risk of myocardial-infarction in patients with hypertension. N Engl J Med 1991, 324(16):1098-1104.
41. Ferrannini E., Santoro D., Manicardi V. The association of essential hypertension and diabetes. Compr Ther 1989, 15(11):51-58.
42. Barrett E.J., Eggleston E.M., Inyard A.C., Wang H., Li G., Chai W., et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009, 52(5):752-764.
43. Vincent M.A., Clerk L.H., Rattigan S., Clark M.G., Barrett E.J. Active role for the vasculature in the delivery of insulin to skeletal muscle. Clin Exp Pharmacol Physiol 2005, 32(4):302-307.
44. Munoz M.C., Argentino D.P., Dominici F.P., Turyn D., Toblli J.E. Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 2006, 24(8):1607-1617.
45. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342(13):905-912.
46. Mason J.M., Dickinson H.O., Nicolson D.J., Campbell F., Ford G.A., Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005, 23(10):1777-1781.
47. Ran J., Hirano T., Fukui T., Saito K., Kageyama H., Okada K., et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 2006, 55(4):478-488.
48. Sharma A.M., Janke J., Gorzelniak K., Engeli S., Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40(5):609-611.
49. Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008, 294(2):E345-E351.
50. Sloniger J.A., Saengsirisuwan V., Diehl C.J., Dokken B.B., Lailerd N., Lemieux A.M., et al. Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. Am J Physiol Endocrinol Metab 2005, 288(6):E1074-E1081.
51. Strazzullo P., Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004, 13(3):325-332.
52. Engeli S., Bohnke J., Gorzelniak K., Janke J., Schling P., Bader M., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45(3):356-362.
53. Iwai M., Chen R., Imura Y., Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007, 20(5):579.
54. Santos S.H., Fernandes L.R., Mario E.G., Ferreira A.V., Porto L.C., Alvarez-Leite J.I., et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008, 57(2):340-347.
55. Porter J.P., Anderson J.M., Robison R.J., Phillips A.C. Effect of central angiotensin II on body weight gain in young rats. Brain Res 2003, 959(1):20-28.
56. Porter J.P., Potratz K.R. Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol Regul Integr Comp Physiol 2004, 287(2):R422-R428.
57. Anker S.D., Negassa A., Coats A.J., Afzal R., Poole-Wilson P.A., Cohn J.N., et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003, 361(9363):1077-1083.
58. Sanders P.M., Russell S.T., Tisdale M.J. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005, 93(4):425-434.
59. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89(6):2548-2556.
60. Saye J.A., Ragsdale N.V., Carey R.M., Peach M.J. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol Cell Physiol 1993, 264(6):C1570-C1576.
61. Shenoy U., Cassis L. Characterization of renin activity in brown adipose tissue. Am J Physiol 1997, 272(3 Pt 1):C989-C999.
62. Cassis L.A., Fettinger M.J., Roe A.L., Shenoy U.R., Howard G. Characterization and regulation of angiotensin II receptors in rat adipose tissue. Angiotensin receptors in adipose tissue. Adv Exp Med Biol 1996, 396:39-47.
63. Mallow H., Trindl A., Loffler G. Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res 2000, 32(11-12):500-503.
64. Campbell D.J., Habener J.F. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 1987, 121(5):1616-1626.
65. Cassis L.A., Saye J., Peach M.J. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11(6 Pt 2):591-596.
66. Gupte M., Boustany-Kari C.M., Bharadwaj K., Police S., Thatcher S., Gong M.C., et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008, 295(3):R781-R788.
67. Rahmouni K., Mark A.L., Haynes W.G., Sigmund C.D. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 2004, 286(6):E891-E895.
68. Cooper R., Forrester T., Ogunbiyi O., Muffinda J. Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J Hypertens 1998, 16(5):571-575.
69. Tuck M.L., Sowers J., Dornfeld L., Kledzik G., Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304(16):930-933.
70. Frederich R.C., Kahn B.B., Peach M.J., Flier J.S. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992, 19(4):339-344.
71. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294(5549):2166-2170.
72. Masuzaki H., Yamamoto H., Kenyon C.J., Elmquist J.K., Morton N.M., Paterson J.M., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112(1):83-90.
73. Gabriely I., Yang X.M., Cases J.A., Ma X.H., Rossetti L., Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001, 281(3):R795-R802.
74. Safonova I., Aubert J., Negrel R., Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J 1997, 322(1):235-239.
75. Harte A.L., McTernan P.G., McTernan C.L., Crocker J., Starcynski J., Barnett A.H., et al. Insulin increases angiotensinogen expression in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 2003, 5(6):462-467.
76. Jones B.H., Standridge M.K., Taylor J.W., Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Physiol 1997, 273(1 Pt 2):R236-R242.
77. Aubert J., Safonova I., Negrel R., Ailhaud G. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochem Biophys Res Commun 1998, 250(1):77-82.
78. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002, 290(3):1084-1089.
79. Jones B.H., Standridge M.K., Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997, 138(4):1512-1519.
80. Kim S., Dugail I., Standridge M., Claycombe K., Chun J., Moustaid-Moussa N. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c. Biochem J 2001, 357(Pt 3):899-904.
81. Yvan-Charvet L., Massiera F., Lamande N., Ailhaud G., Teboul M., Moustaid-Moussa N., et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 2009, 150(3):1421-1428.
82. Weisinger R.S., Stanley T.K., Begg D.P., Weisinger H.S., Spark K.J., Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 2009, 98(1-2):192-197.
83. Furuhashi M., Ura N., Takizawa H., Yoshida D., Moniwa N., Murakami H., et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004, 22(10):1977-1982.
84. Zorad S., Dou J.T., Benicky J., Hutanu D., Tybitanclova K., Zhou J., et al. Long-term angiotensin II AT(1) receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR-gamma. Eur J Pharmacol 2006, 552(1-3):112-122.
85. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami K., et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003, 2(11):1139-1147.
86. Fujimoto Y., Sasaki T., Tsuchida A., Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001, 495(3):197-200.
87. Saye J., Lynch K.R., Peach M.J. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension 1990, 15(6 Pt 2):867-871.
88. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002, 51(6):1699-1707.
89. Crandall D.L., Armellino D.C., Busler D.E., McHendry-Rinde B., Kral J.G. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999, 140(1):154-158.
90. Darimont C., Vassaux G., Ailhaud G., Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994, 135(5):2030-2036.
91. Saint-Marc P., Kozak L.P., Ailhaud G., Darimont C., Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001, 142(1):487-492.
92. Di Filippo C., Lampa E., Tufariello E., Petronella P., Freda F., Capuano A., et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese Zucker rats. Obes Res 2005, 13(11):1909-1914.
93. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004, 109(17):2054-2057.
94. 94. Janke Ja, Schupp Mb, Engeli Sa, Gorzelniak Ka, Boschmann Ma, Sauma Lc, Nystrom FHc, Jordan Ja, Luft FCa, Sharma AMd. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-[gamma] activation. [Article].
95. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16(7):293-299.
96. Fujita M., Hayashi I., Yamashina S., Itoman M., Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002, 294(2):441-447.
97. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98(3):671-679.
98. Sasaki K., Murohara T., Ikeda H., Sugaya T., Shimada T., Shintani S., et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002, 109(5):603-611.
99. Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004, 10(6):625-632.
100. Rupnick M.A., Panigrahy D., Zhang C.Y., Dallabrida S.M., Lowell B.B., Langer R., et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002, 99(16):10730-10735.
101. Cassis L.A., English V.L., Bharawaj K., Boustany C.M. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004, 145(1):169-174.
102. Shetty S., Kusminski C.M., Scherer P.E. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009, 30(5):234.
103. Cassis L.A., Dwoskin L.P. Presynaptic modulation of neurotransmitter release by endogenous angiotensin II in brown adipose tissue. J Neural Transm Suppl 1991, 34:129-137.
104. Cassis L.A. Angiotensin-Ii in brown adipose-tissue from young and adult Zucker obese and lean rats. Am J Physiol 1994, 266(3):E453-E458.
105. Cassis L.A., Marshall D.E., Fettinger M.J., Rosenbluth B., Lodder R.A. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol Endocrinol Metab 1998, 37(5):E867-E876.
106. English V., Cassis L. Facilitation of sympathetic neurotransmission contributes to angiotensin regulation of body weight. J Neural Transm 1999, 106(7-8):631-644.
107. Cassis L.A., Dwoskin L.P. Acute and chronic losartan administration: effect on angiotensin II content and modulation of [3H]norepinephrine release from rat interscapular brown adipose tissue. J Neural Transm Gen Sect 1994, 98(2):159-164.
108. Cassis L.A. Role of angiotensin-Ii in brown adipose thermogenesis during cold-acclimation. Am J Physiol 1993, 265(6):E860-E865.
109. Cassis L., Laughter A., Fettinger M., Akers S., Speth R., Burke G., et al. Cold exposure regulates the renin-angiotensin system. J Pharmacol Exp Ther 1998, 286(2):718-726.
110. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002, 123(5):1667-1676.
111. Takeshita Y., Takamura T., Ando H., Hamaguchi E., Takazakura A., Matsuzawa-Nagata N., et al. Cross talk of tumor necrosis factor-[alpha] and the renin-angiotensin system in tumor necrosis factor-[alpha]-induced plasminogen activator inhibitor-1 production from hepatocytes. Eur J Pharmacol 2008, 579(1-3):426.
112. Torlone E., Rambotti A.M., Perriello G., Botta G., Santeusanio F., Brunetti P., et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991, 34(2):119-125.
113. Ran J., Hirano T., Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens 2005, 23(8):1525-1530.
114. Ran J., Hirano T., Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 2004, 287(5):E955-E961.
115. Ran J., Hirano T., Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004, 287(2):E227-E232.
116. Nabeshima Y., Tazuma S., Kanno K., Hyogo H., Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 2009, 50(6):1226-1235.
117. Folli F., Kahn C.R., Hansen H., Bouchie J.L., Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100(9):2158-2169.
118. Russell S.T., Sanders P.M., Tisdale M.J. Angiotensin II directly inhibits protein synthesis in murine myotubes. Cancer Lett 2006, 231(2):290-294.
119. Carlsson P.O. The renin-angiotensin system in the endocrine pancreas. Jop 2001, 2(1):26-32.
120. Leung P.S., Carlsson P.O. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001, 26(3):155-164.
121. Leung P.S., Chan W.P., Wong T.P., Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999, 160(1):13-19.
122. Tikellis C., Wookey P.J., Candido R., Andrikopoulos S., Thomas M.C., Cooper M.E. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004, 53(4):989-997.
123. Tahmasebi M., Puddefoot J.R., Inwang E.R., Vinson G.P. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999, 161(2):317-322.
124. Carlsson P.O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41(2):127-133.
125. Lau T., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004, 47(2):240-248.
126. Chu K.Y., Leung P.S. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice. Antioxid Redox Signal 2007, 9(7):869-878.
127. Nakayama M., Inoguchi T., Sonta T., Maeda Y., Sasaki S., Sawada F., et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 2005, 332(4):927-933.
128. Shao J., Iwashita N., Ikeda F., Ogihara T., Uchida T., Shimizu T., et al. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006, 344(4):1224-1233.
129. Chu K.Y., Lau T., Carlsson P.O., Leung P.S. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55(2):367-374.
130. Wong T.P., Debnam E.S., Leung P.S. Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane. J Physiol 2007, 584(Pt 2):613-623.
131. Wong T.P., Debnam E.S., Leung P.S. Diabetes mellitus and expression of the enterocyte renin-angiotensin system: implications for control of glucose transport across the brush border membrane. Am J Physiol Cell Physiol 2009, 297(3):C601-C610.
132. Tsang S.W., Cheng C.H., Leung P.S. The role of the pancreatic renin-angiotensin system in acinar digestive enzyme secretion and in acute pancreatitis. Regul Pept 2004, 119(3):213-219.
133. Schwartz M.W., Woods S.C., Porte D., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404(6778):661.
134. Woods S.C., Seeley R.J., Porte D., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 1998, 280(5368):1378-1383.
135. Seeley R.J., Woods S.C. Monitoring of stored and available fuel by the CNS: implications for obesity. Nat Rev Neurosci 2003, 4(11):901.
136. Krause E.G., Melhorn S.J., Davis J.F., Scott K.A., Ma L.Y., de Kloet A.D., et al. Angiotensin type 1 receptors in the subfornical organ mediate the drinking and hypothalamic-pituitary-adrenal response to systemic isoproterenol. Endocrinology 2008, 149(12):6416-6424.
137. Sernia C. Location and secretion of brain angiotensinogen. Regul Pept 1995, 57(1):1-18.
138. Richoux J.P., Bouhnik J., Clauser E., Corvol P. The renin-angiotensin system in the rat brain. Immunocytochemical localization of angiotensinogen in glial cells and neurons. Histochemistry 1988, 89(4):323-331.
139. Elased K.M., Cunha T.S., Marcondes F.K., Morris M. Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. Exp Physiol 2008, 93(5):665-675.
140. Saavedra J.M., Chevillard C. Angiotensin-converting enzyme is present in the subfornical organ and other circumventricular organs of the rat. Neurosci Lett 1982, 29(2):123-127.
141. Saavedra J.M., Fernandez-Pardal J., Chevillard C. Angiotensin-converting enzyme in discrete areas of the rat forebrain and pituitary gland. Brain Res 1982, 245(2):317-325.
142. Ganten D., Minnich J.L., Granger P., Hayduk K., Brecht H.M., Barbeau A., et al. Angiotensin-forming enzyme in brain tissue. Science 1971, 173(991):64-65.
143. Lippoldt A., Fuxe K., Luft F.C. A view of renin in the brain. J Mol Med 2001, 79(2-3):71-73.
144. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortès C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997, 18(4):383.
145. Moellenhoff E., Blume A., Culman J., Chatterjee B., Herdegen T., Lebrun C.J., et al. Effect of repetitive icv injections of ANG II on c-Fos and AT1-receptor expression in the rat brain. Am J Physiol Regul Integr Comp Physiol 2001, 280(4):R1095-R1104.
146. Kisley L.R., Sakai R.R., Flanagan-Cato L.M., Fluharty S.J. Estrogen increases angiotensin II-induced c-Fos expression in the vasopressinergic neurons of the paraventricular nucleus in the female rat. Neuroendocrinology 2000, 72(5):306.
147. Johren O., Imboden H., Hauser W., Maye I., Sanvitto G.L., Saavedra J.M. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997, 757(2):218-227.
148. Seltzer A., Tsutsumi K., Shigematsu K., Saavedra J.M. Reproductive hormones modulate angiotensin II AT1 receptors in the dorsomedial arcuate nucleus of the female rat. Endocrinology 1993, 133(2):939-941.
149. Aguilera G., Young W.S., Kiss A., Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin-II. Neuroendocrinology 1995, 61(4):437-444.
150. Sumitomo T., Suda T., Nakano Y., Tozawa F., Yamada M., Demura H. Angiotensin-II increases the corticotropin-releasing factor messenger-ribonucleic-acid level in the rat hypothalamus. Endocrinology 1991, 128(5):2248-2252.
151. Fuzesi T., Wittmann G., Liposits Z., Lechan R.M., Fekete C. Contribution of noradrenergic and adrenergic cell groups of the brainstem and agouti-related protein-synthesizing neurons of the arcuate nucleus to neuropeptide-Y innervation of corticotropin-releasing hormone neurons in hypothalamic paraventricular nucleus of the rat. Endocrinology 2007, 148(11):5442-5450.
152. Li D.-P., Chen S.-R., Pan H.-L. Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci 2003, 23(12):5041-5049.
153. Li D.-P., Pan H.-L. Angiotensin II attenuates synaptic GABA release and excites paraventricular-rostral ventrolateral medulla output neurons. J Pharmacol Exp Ther 2005, 313(3):1035-1045.
154. Rowland N.E., Fregly M.J. Comparison of the effects of the dipeptidyl peptidase inhibitors captopril, ramipril, and enalapril on water-intake and sodium appetite of Sprague-Dawley rats. Behav Neurosci 1988, 102(6):953-960.
155. Schiffrin E.L., Genest J. Mechanism of captopril-induced drinking. Am J Physiol Regul Integr Comp Physiol 1982, 242(1):R136-R140.
156. Kasper S.O., Carter C.S., Ferrario C.M., Ganten D., Ferder L.F., Sonntag W.E., et al. Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics 2005, 23(3):311-317.